Tiziana's StemPrintER is a multi-gene prognostic assay intended for the prediction of the risk of recurrence in luminal, estrogen receptor-positive HER2-negative breast cancer patients, based on the detection of 20 cancer stem cell markers. The assay has been evaluated in an initial retrospective validation study using a consecutive cohort of approximately 2,400 patients with breast cancer. Two posters were selected for presentation at virtual ASCO 2020 Conference. One demonstrating the superiority of StemPrintER versus the market leader, Oncotype DX, in predicting recurrence in ER+/HER2- postmenopausal breast cancer patients was selected for discussion session. The second poster describing results on prediction of distant recurrence using a next generation StemPrintER model, named SPARE, presented in a separate ASCO session, showed even more refined accuracy than standard clinicopathological markers in predicting risk of distant recurrence.
On May 29, 2020 Tiziana announced to demerge StemPrintER and SPARE (together "StemPrintER") personalized medicine businesses into a separate independent entity.